

AMENDMENTS TO THE CLAIMS

1-48. (Canceled)

49. (Currently Amended) A method of treatment, comprising:

a) providing:

i) a mammal having a plurality of symptoms of sepsis, wherein said symptoms comprise arterial hypotension and at least one selected from the group consisting of metabolic acidosis, fever, decreased systemic vascular resistance, tachypnea, and organ failure,

ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and

b) administering said preparation to said mammal wherein said symptoms are reduced.

50. (Previously Presented) The method of Claim 49, wherein said antibodies are polyclonal.

51. (Currently Amended) A therapeutic composition for use with a mammal having at plurality of symptoms of sepsis, wherein said symptoms comprise arterial hypotension and at least one selected from the group consisting of metabolic acidosis, fever, decreased systemic vascular resistance, tachypnea, and organ failure, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.

52. (New) A method of treatment, comprising:

a) providing:

i) a mammal having sepsis,

ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and

b) administering said preparation to said mammal wherein said sepsis is reduced.

53. (New) The method of Claim 52, wherein said antibodies are polyclonal.

54. (New) A therapeutic composition for use with a mammal having sepsis, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.

55. (New) A method of treatment, comprising:

a) providing:

i) a mammal having septic shock,

ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and

b) administering said preparation to said mammal wherein said septic shock is reduced.

56. (New) The method of Claim 49, wherein said antibodies are polyclonal.

57. (New) A therapeutic composition for use with a mammal having septic shock, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.